New combinations emerging as immunotherapies become the backbone therapy

Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective single agents, they’re shaping up to be the backbone for a host of new combination therapies.

Learn what an immunotherapy-centric treatment algorithm means for patients and drug manufacturers in KOL Insight: Malignant Melanoma.

Twelve North American and European KOLs’ answer key questions about 9 marketed melanoma treatments and 5 currently in the pipeline.

You’ll find out which immunotherapies are most effective, and hear how they’re likely to be combined with existing and pipeline BRAF/MEK inhibitors, vaccines and immunostimulants, and other small-molecule therapies. You’ll also get insight into the key clinical trials that are shaping the market.